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INTRODUCTION
Mevalonic acid is an essential intermediate in the synthesis of both plant and animal sterols (3, 4) . The further finding that the primary feedback control of cholesterogenesis is located at the site of mevalonate synthesis (5) (6) (7) (8) has stimulated an intense interest in the metabolic fate of this cholesterol precursor. To date, two major metabolic pathways for circulating mevalonate have been documented in animals. The first, a sterol pathway, leads to the synthesis of cholesterol (9) (10) (11) (12) . The second, or nonsterol, pathway shunts mevalonate away from sterol production (13) and ultimately results in its oxidation to CO2 (14, 15) . In addition to these major pathways of mevalonate metabolism, quantitatively minor pathways leading to ubiquinone and dolichol have been described (16) (17) (18) .
Previous in vivo and in vitro studies have demionstrated that the kidneys, rather than the liver, are the most active site of mevalonate metabolism by both the sterol (12, 15, 19, 20) and the nonsterol, or shunt pathways (15, (20) (21) (22) . Studies in rats have further shown that there are major sex differences in circulating mevalonate metabolism by these two mechanisms (23) . First, the female rat metabolizes circulating mevalonate by the shunt pathway at twice the rate of the male, a difference accounted for almost entirely by the greater ability of the female kidney to convert mevalonate to CO2. Second, the male rat converts significantly more circulating mevalonate to cholesterol than does the female. These findings are of particular interest because they represent the first evidence of a sex difference in cholesterol metabolism in any animal species. The present report extends these observations to humans and reveals that women metabolize circulating mevalonate by the shunt pathway to a significantly greater extent than do men.
METHODS
Subjects. Six men and five women participated in the study. The subjects were Caucasians betweeen the ages of 24 and 40 yr; they were in good health and taking no medications. None had a personal or family history of diabetes mellitus, renal disease, liver disease, or hyperlipidemia. Urinalysis and fasting glucose, urea nitrogen, and creatinine levels were normal in all subjects; pregnancy tests, carried out in the female subjects the day before the study, were negative. Informed consent was obtained from all subjects. monitored for CO2 concentration and radioactivity. For these procedures, an on-stream analyzer complex consisting of a flow meter, an ionization chamber with vibrating reed electrometer, and an infrared CO2 analyzer were used. Blood samples were obtained from the contralateral antecubital vein at 5-, 20-, 60-, 180-, and 540-min intervals during the study and at 1-, 2-, and 3-wk intervals after its conclusion. Total urine output was collected for 48 h. The subjects were allowed to eat 3-4 h after beginning the study. At several additional intervals throughout the study, air collection was discontinued for 15 min. Five men and four women were studied over 9-h periods, and the remaining man and woman were studied for 17 h.
C02 collection. During the study the subject wore a plexiglass helmet, tightly sealed at the shoulders. A flow system provided air at 7 liters/min from a compressed air tank. The (1:5) for 60 min. The areas on the plates that corresponded to standards of cholesterol, lanosterol, and squalene were placed in scintillation counting vials to which 10 ml of scintillation counting solution was added. The 14C was assayed at the window settings described.
Long-chain fatty acids. After the three basic extractions with petroleum ether to remove nonsaponifiable lipids, the water phase was acidified to pH 2 with HCI. The fatty acids were extracted with petroleum ether and then dried, and their "4C content was assayed in the manner described for the nonsaponifiable lipids. Urine studies. Urine samples were collected by four male and four female subjects for 0-6, 6-12, 12-24, and 24-48 h. The volume of urine was measured and 0.1 ml of each urine collection was assayed for 14C content in 10 ml ofthe counting solution as described above. From the 0-6-h urine fraction, 10 ml of urine was acidified to pH 2 significant (P < 0.001). During the 9 h of study, the males had expired an average of 70% (range, 64-73%; n = 4) and the females an average of 60% (range, 44-66%; n = 4) of the calculated total G4CO2 to infinity. These data indicate that the great majority of the metabolism of [14C]mevalonate to 14CO2 occurred during the 9 h of study.
To confirm that first-order kinetics characterized the expiration of 14CO2 from mevalonate over a more extended period of time, we studied one male and female subject for 17 h. At the end of this period, 14CO2 was no longer detectable in the expired air of either subject. The data in this study confirmed that first-order kinetics characterized the metabolism of [14C]mevalonate to GO2 over at least a 17-h period and furthermore, that the values calculated from 9-h G4CO2 collections predicted values experimentally observed during the 17-h collection for the male and female subject studied: male calculated 17-h value, 3 .89 x 106 dpm; observed 17-h value, 3 .69 x 106 dpm; female calculated 17-h value, 4 .39 x 106 dpm; observed 17-h value, 4.50 x 106 dpm.
To determine the reproducibility of results, mevalonate metabolism in female subject M.V. was studied twice with an interval exceeding six months between experiments. The results observed (18.3 vs. 16 .1%) confirmed the reproducibility of the procedure in determining shunt pathway activity.
As noted earlier in rats, the majority of the oxidation of mevalonate to CO2 occurs in the kidney. All of our subjects had normal renal function as reflected by plasma blood urea nitrogen and creatinine. To evaluate renal function further, renal plasma flow was determined in several subjects. No significant sex difference in renal plasma flow was observed (P > 0.1) (Table IV) ; moreover, on regression analysis no significant correlation existed between individual shunt pathway activity and renal plasma flow (r = -0.32).
Labeled cholesterol was found in the serum and erythrocytes of both the male and female subjects and attained maximum activity at 9 h in both sexes (Table  V) . The amounts of [14C]cholesterol per milliliter of serum or erythrocytes during the 3 wk of observation were similar in the male and female subjects (P > 0.1). Labeled free fatty acids, lanosterol, and squalene were not detected in either the serum or erythrocytes of either the male or female subjects, perhaps because of the small amount of labeled mevalonate administered. Table VI shows the percentage ofinjected ['4C]mevalonate excreted in the urine in 6 and 48 h. The majority of the 14C was excreted during the first 6 h. Female subjects excreted slightly more 14C than males, but this difference was not statistically significant (P > 0.1). Thin-layer chromatography of ethyl ether-extracted urine revealed that the 14C in the urine was present as a single spot, which migrated identically with [14C]-mevalonate. Presumably, the major portion of the 14C present in the urine of both the male and female subjects represented unmetabolized S-mevalonate (10).
DISCUS SION
In 1974, Edmond and Popjak (13) first presented evidence that mevalonate is metabolized in the intact rat by a nonsterol, or shunt, pathway. The next year, Fogelman et al. (14) further demonstrated that this pathway is present in human males. Subsequent studies from our laboratory have shown that in the rat there is a marked sex difference in circulating mevalonate metabolism by the shunt pathway (23) . In these in vivo studies, the female rat was found to metabolize more than 21 .0% of circulating mevalonate to CO2 by this mechanism, whereas the male rat oxidized only 11.6% ofmevalonate to C02. The purpose Difference between male and female 6-h and 48-h excretion is not significant (P > 0.1). subsequent metabolites of mevalonate. Similarly, differences in renal function or renal blood flow cannot explain the observed sex difference in the oxidation of circulating mevalonate to CO2.
The concentration of plasma mevalonate in humans has recently been reported (25) . The concentrations ranged from 20 to >60 pmol/ml but in a majority of individuals ranged between 30 and 50 pmol/ml. Unfortunately, from the published data it could not be determined if a sex difference in plasma mevalonate levels was present. Nevertheless, a difference in plasma mevalonate concentration would not be expected, as noted earlier, to alter the total quantity of 14CO2 expired at infinity, but rather vould only change the production rate of '4CO2. Additionally, the amount of exogenous mevalonate administered was approximately 10 times greater than the entire circulating pool, which further reduces the possibility that differences in the circulating pool of mevalonate are the basis for the observed sex differences in metabolism.
Total plasma cholesterol levels and VLDL, LDL, and HDL cholesterol concentrations were normal in all our subjects. Within the limitation of the small number of subjects studied, shunt pathway activity did not correlate significantly with age, weight, cholesterol levels, triglyceride levels, or VLDL, LDL, and HDL cholesterol concentrations.
In our earlier study in rats, the female exhibited greater mevalonate shunt activity, whereas the male rat copverted significantly more circulating mevalonate to cholesterol in the kidney than did the female. In this study of mevalonate metabolism in humans, we observed that the amounts of ['4C]mevalonate incorporated into serum and erythrocyte cholesterol were similar in the two sexes. This finding does not, of course, rule out the possibility that there are sex differences in the human sterol pathway of mevalonate metabolism. A more definitive answer to this question requires the study of cholesterogenesis in tissues, such as kidney and liver, which represent the primary sites of cholesterol synthesis from circulating mevalonate (12, 15) .
This study extends to human beings our earlier finding that the female uses the shunt pathway of mevalonate metabolism to a significantly greater extent than the male. This observation, moreover, represents the first evidence of a sex difference in humans in the metabolism of this cholesterol precursor. The overall impact of the greater mevalonate shunt activity on cholesterol balance in women is yet to be determined.
